Clinical

Despite the fact that post-bronchodilator spirometry is required for the diagnosis of chronic obstructive pulmonary disease, an analysis of primary care clinics found only 19% of patients diagnosed with the disease had undergone spirometry testing.

Three important patient-reported outcomes can help predict hospitalizations among patients with chronic obstructive pulmonary disease, potentially helping clinicians to categorize patients' level of risk and design preventive interventions and proper care.

A study published in the journal Cancer presents the financial impact of cancer on a survivor and his family.

Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.

The drug is awaiting an FDA verdict next week.

As the date for the comment period on the proposed guidance by HHS on 340B drug pricing draws near, read about the program and its impact on healthcare overall.

Published in JAMA Oncology, the study found a significant difference in quality and access to care for black patients diagnosed with localized prostate cancer.

Patients with cancer in the urology clinic at a VA hospital in Arizona may have suffered adverse outcomes due to clinical disconnect and staff shortage.

Patients with metastatic pancreatic cancer who have progressed on gemcitabine now have the option of Onivyde combined with leucovorin/fluorouracil.

A study published in the Journal of the American College of Surgeons found that including patients in the Enhanced Recovery program has a dramatic impact on their recovery post surgery.

A presentation at the annual meeting of the American Society for Radiation Oncology underscored the importance of patient-centered care and the benefit of incorporating the patient voice in advanced oncology care.

A letter published in JAMA Internal Medicine questions the FDA's acceptance of surrogate endpoints for what the authors describe as "costly, toxic drugs that do not improve overall survival."

A new evidence-based guidance update provided by the American Cancer Society, published yesterday in JAMA Internal Medicine, recommends a delay in initiating screening mammograms in women with an average risk of developing the disease.

A panel discussion at the PMC/BIO Solutions Summit in Washington, DC, saw an exchange on widespread and appropriate education of personalized medicine among payers, providers, patients, and families.

NCCN Evidence Blocks add affordability to Guidelines recommendations on safety, efficacy, quality, and consistency of regimens.